Drugs / Ioforminol
Ioforminol
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01672996 | Jul → Aug 2012 | — | GE Healthcare | Completed | No outcome recorded |
| Phase 1/2 | NCT01004770 | Oct 2009 → Feb 2010 | — | GE Healthcare | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01252810 | Nov 2010 → Dec 2012 | chronic renal failure syndrome, congestive heart failure, diabetes mellitus | GE Healthcare | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ioforminol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01672996 ↗ |
| Known as | AN113111 | “GE-145 (AN113111) Injection” NCT01004770 ↗ |
| Known as | FEK-256-062 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219417 ↗ |
| Known as | GE-145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01252810 ↗ |
| Modality | Diagnostic / imaging agent | “overall diagnostic quality following administration of GE-145” NCT01004770 ↗ |
| Route | Intravenous | “GE-145-320 mg I/mL as a single iv. administration” NCT01252810 ↗ |